by Leslie Cantu, Medical University of South Carolina Credit: Unsplash/CC0 Public Domain Most multiple myeloma patients undergoing stem cell transplants of their own cells can safely be treated in an outpatient setting, thus reducing costs, reducing hospitalization time and potentially increasing patient satisfaction, according to a retrospective study published in Hematology/Oncology and Stem Cell Therapy by MUSC Hollings Cancer...
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IMAGE: SHOWN ARE MULTIPLE MYELOMA CELLS FROM A PATIENT. AN INTERNATIONAL PHASE 3 CLINICAL TRIAL LED BY WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS HAS SHOWN THAT THE INVESTIGATIONAL DRUG MOTIXAFORTIDE — WHEN COMBINED WITH THE STANDARD THERAPY FOR MOBILIZING STEM CELLS — SIGNIFICANTLY INCREASED THE NUMBER OF STEM...
by The Mount Sinai Hospital Treatment breakdown of the multiple myeloma patient cohort. (A) Flow chart showing that the initial retrospective query yielded 115 RRMM patients enrolled on a BiAb clinical trial at Mount Sinai Hospital. Out of those 115 patients, we focused on 58 patients who came off the trials and went on to...
UT SOUTHWESTERN MEDICAL CENTER IMAGE: A NEW TYPE OF CAR T-CELL THERAPY MORE THAN TRIPLES THE EXPECTED LENGTH OF REMISSION FOR MULTIPLE MYELOMA PATIENTS WHO HAVE RELAPSED SEVERAL TIMES, ACCORDING TO AN INTERNATIONAL CLINICAL TRIAL WITH UT SOUTHWESTERN AS THE LEAD ENROLLING SITE. CREDIT: UT SOUTHWESTERN MEDICAL CENTER DALLAS – March 8, 2021 – A...
